Novotech is a top 3 clinical trial contractor operating in Korea
post-template-default,single,single-post,postid-22004,single-format-standard,bridge-core-2.5.9,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-title-hidden,transparent_content,qode-theme-ver-24.4,qode-theme-bridge,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.2,vc_responsive

 Novotech is a top 3 clinical trial contractor operating in Korea

According to data on the number of Investigational New Drug (IND) clinical trial approvals from the Korean Ministry of Food and Drug Safety (MFDS), Novotech is one of the top 3 clinical trial contractors operating in Korea.

Novotech announced the news during KoNECT (Korea National Enterprise for Clinical Trials)’s international conference. The statistics were calculated by reviewing the number of IND clinical trials submitted and approved over the past 12 months as well as existing data found on the MFDS website.

Dr Yooni Kim, Executive Director and Head of Asia Operations at Novotech, said “[t]he reason why Novotech ranks so high in the number of clinical trial approvals for new drugs is because Novotech has extensive knowledge and experience in each country that we are actively working in.”

Further, Dr Kim stated that Novotech’s deeper understanding of local regulations and clinical trial practices allows the company to obtain the support of biotech sponsors to proceed with the trials.

Novotech is the largest biotechnology specialist contract research organisation (CRO) in the Asia-Pacific and also operates in North America.

Click here to read the article (Korean).

Click here to read Novotech’s media release.